Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

### 144: Filer Information

Filer CIK 0001817838
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name Phone

E-Mail Address

#### 144: Issuer Information

Name of Issuer CORCEPT THERAPEUTICS INC

SEC File Number 000-50679

149 COMMONWEALTH DRIVE

Address of Issuer

MENLO PARK
CALIFORNIA

94025

Phone 650.688.8803

Name of Person for Whose Account the Securities are To Be Sold Lyon Joseph Douglas

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Securities
Common	Stifel Nicolaus & Company Inc. 501 North Broadway St. Louis MO 63102	5000	127000.00	104110000	05/09/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

Title of the	Date you	Nature of	Name of	ls	Date	Amount of	Date of	Nature of
Class	Acquired	Acquisition	Person from	this	Donor	Securities	<b>Payment</b>	Payment *
	_	Transaction			Acquired	Acquired		

Whom Acquired	a Gift?		
Corcept Therapeutics Inc.		5000	05/09/2024 Cash

Common 05/09/2024 Stock Option Exercise

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	<b>Gross Proceeds</b>
Joseph D. Lyon 149 Commonwealth Drive Menlo Park CA 94025	Corcept Therapeutics Inc.	02/16/2024	1000	26000.00
Joseph D. Lyon 149 Commonwealth Drive Menlo Park CA 94025	Corcept Therapeutics Inc.	04/01/2024	500	13003.50
Joseph D. Lyon 149 Commonwealth Drive Menlo Park CA 94025	Corcept Therapeutics Inc.	04/04/2024	5443	141524.00
Joseph D. Lyon 149 Commonwealth Drive Menlo Park CA 94025	Corcept Therapeutics Inc.	05/02/2024	10830	281580.00

# 144: Remarks and Signature

Remarks
Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

05/09/2024
05/08/2023

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Joseph D. Lyon

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)